Alcohol: Drug or Social Amenity?

Pharmacy Times, Volume 0,0

Alcohol is a drug, social lubricant, and agent of abuse; alcohol abuse and dependence exist along a continuum, and different approaches can help.

Ms. Wick is a senior clinical researchpharmacist at the National CancerInstitute, National Institutes of Health,Bethesda, Maryland. The views expressedare those of the author and not those ofany government agency.

Individuals today drink twothirds less than they did in the1780s—when alcohol was a pharmacopeialstaple, a community ritual,and a safer beverage than taintedwater or spoiled milk.1 National surveysindicate that US alcohol consumptionand sales have decreasedsince the 1980s.2 Regardless, alcoholdependence and abuse are continuingconcerns.

Understanding alcohol and problemdrinking is like assembling a bicyclewithout directions—befuddling. Studiesuse conflicting methodologies andinconsistent definitions. People withalcohol problems may be unreliablehistorians. The relationship betweenhealth risks and alcohol consumption isnonlinear. Clinicians often misdiagnosealcohol-related conditions, and considerabledebate exists on abstinence versusmoderation.

A Matter of Degree

Individuals who meet 3 of the criteriain the Diagnostic and StatisticalManual of Mental Disorders, FourthEdition (DSM-IV) are considered alcoholdependent (Table). Abusers are notdependent, but drink despite emotional,occupational, physical, psychological,or social problems.3 Abuse includesbinge drinking or drinking too much toooften without dependency.

When discussing alcohol,sex and age are significant.Men of any age are more likelyto drink than women peers.4A recent study determinedthat in the United States,alcohol abuse disproportionatelyaffects the youth (31%of problem drinkers), andyoung adults rarely seek helpfor drinking; periodic heavydrinking is common.5

What's One Drink?

The Department of Healthand Human Services (HHS)defines 1 drink as 0.5 oz or 15g of alcohol (eg, 12 oz of beer,5 oz of wine, 1.5 oz of 80-proofdistilled spirits). HHS definesmoderate drinkingas 2drinks daily for men and 1 forwomen and heavy consumptionas any amount abovemoderate levels.6 Men absorband metabolize alcohol fasterand have a larger volume of distribution,so drink-for-drink, men's blood alcohollevels are lower than women's.

Twenty years of daily alcohol intakeof 72 oz of beer, 1 L of wine, or 8 ozof distilled spirits will lead to scarring,fibrosis, and portal vein hypertensionin men. In women, the risk thresholdis 50% to 75% lower, and even throughabstinence, the elevated risk persists.7The leaner body mass of the elderlyincreases their sensitivity to alcohol;their medical conditions and concurrentdrugs also are concerns. HHS recommendsthat elders consume no morethan 1 drink daily.6

Benefits of Alcohol

Whereas alcohol increases the risk formany conditions, studies link low-tomoderatealcohol intake with a lowerrisk for some conditions. This createsa J-shaped alcohol?risk relationship(Figure), which indicates that for someconditions (eg, coronary artery disease,thrombotic disease), abstainers areat a higher risk than moderate drinkers.Moderate drinking, therefore, maybe beneficial. It potentially improvesulcerative colitis, macular degeneration,and upper respiratory infection.8-15Interpretation of these findings is complicated,however, because moderatedrinkers often have other, unidentifiedrisk-lowering habits.

Abstinence Versus ControlledDrinking

Most Americans consider alcoholism aprogressive, irreversible disease markedby loss of control. US health care providershave traditionally preferred treatmentmodels that favor abstinence,and most still avoid recommendingcontrolled drinking or moderation.Abstinence advocates insist that controlleddrinking merely excuses alcoholismand that eventually, individualswill drink heavily again. Other modelsacknowledge controlled drinking, citingresearch findings that up to 75% of heavydrinkers are not chemically dependent,but abusers. Drinkers themselves maybe uninterested in abstinence andmay prefer to try controlled drinking.Moderation advocates also suggest thatthe American medical superstructure'sfocus on abstinence has precluded fundingto study alternatives.6,16,17

Heavy drinkers often reduce theiralcohol consumption without formalinterventions or programs. Most expertsindicate that alcohol abuse decreaseswith age. Spontaneous remission, treatmentinterventions, and earlier alcoholrelatedmortality partially explain thetrend. Evidence suggests that womenmay control drinking more successfullythan men, and moderate drinking mightbe achievable for stress-triggered drinkers.6,16,17 Many experts believe severelydependent drinkers are more successfulwith abstinence approaches, but moderationis appropriate for those withmoderate problems.18,19 For people whoavoid Alcoholics Anonymous?type approachesbecause of their reliance on ahigher power and unyielding structure,interventions and developing cognitivebehavioral skills such as coping skills,contracts, and consumption-reductionstrategies work better.6,16,17

Regardless, Risks Exist

Alcohol's circular and progressive effectsbegin with an assault on the gastrointestinalsystem, where it harms themucosa and impairs vitamin absorption.Avitaminosis may cause neurologicdamage. Anemias, created byinefficient, ineffective blood synthesis,challenge the heart, lungs, and liver.Elevated lipids follow, raising the spectorof cardiovascular problems. Theseproblems destroy baseline health andinvite infection. Concurrent smokingand daily drinking triple the risk of cirrhosisand increase the risk of head andneck cancer.9

Pharmacologic Moderation orAbstinence

In the past few years, drug treatmentshave increased the likelihood thatpeople with alcohol problems find lesscostly, more convenient, office-basedhelp.20 Indeed, office-based may bethis field's new buzz word. The idealpharmacologic intervention for alcoholdependence or abuse would decreasethe craving, block the reinforcementthat intoxication delivers, and be free ofside effects. Although no such agent isavailable, progress is being made, andcoupled with brief or ongoing behavioralinterventions, these drugs can helppeople with drinking problems improvetheir health prospects and quality of lifeimmensely.

Acamprosate

Tested in multicenter, placebo-controlled,clinical trials with >4500 patients,acamprosate increased abstinence rateswhen used with multidisciplinary psychosocialor behavioral therapies; however,study findings have been inconsistent.Mild side effects include diarrhea.21

Disulfiram

Disulfiram produces an unpleasant alcohol intolerance by blocking acetaldehyde oxidation, increasing circulating acetaldehyde levels up to 10 times higher than normal. Alcohol exposure causes flushing, throbbing headache, nausea, vomiting, and respiratory symptoms. Patients must be highly motivated. Therapy can cause hepatic dysfunction, and chronic use of disulfiram is rare.22

Criteria for Alcohol Dependence

An alcohol-dependent person must meet 3 of the following criteria:

  • Persistent desire to drink or unsuccessful attempts at moderation
  • Inability to exercise control over drinking once begun
  • Withdrawal symptoms or avoidance of withdrawal
  • Tolerance—the need to increase intake to experience a high
  • Spending too much time drinking or recovering from drinking
  • Giving up or reducing normal activities in favor of drinking
  • Continuing to drink in the presence of a physical or psychological problem exacerbated by drinking

Adapted from reference 3.

Naltrexone

Approved in 1995 for alcoholism, naltrexone tempers alcohol's euphoric effects. Available orally and as a monthly injection, naltrexone should not be started until patients are abstinent for 4 days. The best candidates are patients who have been drinking for <20 years, have strong family histories of alcoholism, experience strong cravings, are employed, and have a spouse or a similar social support system.20,23

Under Study

Nalmefene is a newer opioid antagonist lacking agonist activity or abuse potential. Its bioavailability and half-life are better than naltrexone's; it causes no dose-dependent liver toxicity and binds more competitively with opioid receptor subtypes thought to reinforce drinking.24 Topiramate's ability to affect multiple systems seems to decrease alcohol cravings, especially in people with severe,chronic alcohol dependence.25,26 Other agents with potential include baclofen27 and ondansetron.28-30

References

  • Gibert Murdoch C. Domesticating Alcohol: Man, Women and Alcohol in America, 1870-1940. Baltimore, MD: The Johns Hopkins Press; 2006.
  • Shute N. The drinking dilemma. U.S. News & World Report. 1997;123:54-64.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). 4th ed. Washington, DC: APA Press; 2000.
  • Grant BF. Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: results of the National Longitudinal Alcohol Epidemiologic Survey. J Stud Alcohol. 1997;58:464-473.
  • Moss HB, Chen CM, Yi HY. Subtypes of alcohol dependence in a nationally representative sample. Drug Alcohol Depend. 2007;91:149-158.
  • U.S. Department of Health and Human Services. 10th Special Report to the U.S. Congress on Alcohol and Health. June 2000, NIH publication number 00-1583.
  • Maher JJ. Exploring alcohol's effects on liver function. Alcohol Health Res World. 1997;21:5-12.
  • Klatsky AL, Armstrong MA, Friedman GD. Alcohol and mortality. Ann Intern Med. 1992;117:646-654.
  • Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet. 1991;338:464-468.
  • Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med. 1997;337:1705-1714.
  • Scherr PA, LaCroix AZ, Wallace RB, et al. Light to moderate alcohol consumption and mortality in the elderly. J Am Geriatr Soc. 1992;40:651-657.
  • Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329:1829-1834.
  • Suh I, Shaten BJ, Cutler JA, Kuller LH. Alcohol use and mortality from coronary heart disease: the role of high-density lipoprotein cholesterol. The Multiple Risk Factor Intervention Trial Research Group. Ann Intern Med. 1992;116:881-887.
  • Pahor M, Guralnik JM, Havlik RJ, et al. Alcohol consumption and risk of deep venous thrombosis and pulmonary embolism in older persons. J Am Geriatr Soc. 1996;44:1030-1037.
  • Obisesan TO, Hirsch R, Kosoko O, Carlson L, Parrott M. Moderate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANES-1. J Am Geriatr Soc. 1998;46:1-7.
  • Walitzer KS, Connors GJ. Thirty-month follow-up of drinking moderation training for women: a randomized clinical trial. J Consult Clin Psychol. 2007;75:501-507.
  • Hersey B. The controlled drinking dilemma: A review of four decades of acrimony. www.doctordeluca.com/library/abstinenceHR/FourDecadesAcrimony-print.htm. Accessed February 17, 2003.
  • Humphreys K, Klaw E. Can targeting nondependent problem drinkers and providing internet-based services expand access to assistance for alcohol problems? A study of the moderation management self-help/mutual aid organization. J Stud Alcohol. 2001;62:528-532.
  • Linke S, Murray E, Butler C, Wallace P. Internet-based interactive health intervention for the promotion of sensible drinking: patterns of use and potential impact on members of the general public. J Med Internet Res. 2007;9:e10.
  • Kuehn BM. New therapies for alcohol dependence open options for office-based treatment. JAMA. 2007;298:2467-2468.
  • Mason BJ, Crean R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother. 2007;7:1465-1477.
  • Johnson BA. Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol. 2008;75:34-56.
  • Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2000;:CD001867.
  • Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res. 2007;31:1179-1187.
  • Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1641-1651.
  • Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction. 2006;101:1561-1568.
  • Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370:1915-1922.
  • Dawes MA, Johnson BA, Ait-Daoud N, Ma JZ, Cornelius JR. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav. 2005;30:1077-1085.
  • Johnson BA, Ait-Daoud N, Ma JZ, Wang Y. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcohol Clin Exp Res. 2003;27:1773-1779.
  • Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl). 2002;160:408-413.